Skip to main content
. 2019 Jul 4;9:9704. doi: 10.1038/s41598-019-46039-5

Table 2.

Characteristics of the study participants matched on follow-up time and year of entry.

Variables Total (n = 360) Infection cases (n = 120) Controls (n = 240)
Age on diagnosis, years* 36.3 ± 13.0 36.0 ± 14.5 36.5 ± 12.1
Sex, female (%)* 323 (89.7) 106 (88.3) 217 (90.4)
WBC, /µL 6,708.1 ± 4,912.6 6,895.4 ± 5,038.8 6,614.5 ± 4,856.3
N/L ratio 7.6 ± 10.7 8.1 ± 12.7 7.4 ± 9.6
Hemoglobin, /µL 11.6 ± 1.9 11.1 ± 2.2 11.8 ± 1.7
Platelet, × 103/µL 206.7 ± 103.5 212.3 ± 108.8 204.0 ± 100.9
ESR, mm/h 35.5 ± 25.8 37.2 ± 30.9 34.6 ± 22.9
Complement 3, mg/dL 84.3 ± 39.9 78.2 ± 40.2 87.4 ± 39.5
Complement 4, mg/dL 18.9 ± 11.7 18.4 ± 13.4 19.2 ± 10.8
Anti-dsDNA Ab, IU 28.0 ± 34.9 31.7 ± 35.8 26.1 ± 34.4
Oral ulcer, n (%) 296 (82.2) 102 (85.0) 194 (80.8)
Arthritis, n (%) 241 (66.9) 76 (63.6) 165 (68.8)
Nephritis, n (%) 244 (67.8) 49 (40.8) 67 (27.9)
Serositis, n (%) 73 (20.3) 36 (30.0) 37 (15.4)
Hematologic involvement, n (%) 105 (29.2) 50 (41.7) 55 (22.9)
Hydroxychloroquine, n (%) 314 (87.2) 96 (80.0) 218 (90.8)
Total dose of GCs, mga 4,799.3 ± 6,653.5 5,227.3 ± 6,190.7 4,585.4 ± 6,875.7
Mean dose of GCs, mg/da 8.3 ± 14.6 10.4 ± 14.6 7.2 ± 14.5
Dose of GCs
≤7.5 mg/da 247 (68.6) 70 (58.3) 177 (73.8)
>7.5 mg/da 113 (31.4) 50 (41.7) 63 (26.3)
Immunosuppressive drugs 172 (47.8) 63 (52.5) 109 (45.4)
Survival time, days* 1,000 ± 1,040.2 1,000 ± 1,043.1 1,000 ± 1,040.9
Cohort entry, year*
1995–1997 8 (2.2) 3 (2.5) 5 (2.1)
1998–2000 4 (1.1) 1 (0.8) 3 (1.3)
2001–2003 52 (14.4) 17 (14.2) 35 (14.6)
2004–2006 97 (26.9) 34 (28.3) 63 (26.3)
2007–2009 80 (22.2) 25 (20.8) 55 (22.9)
2010–2012 87 (24.2) 30 (25.0) 57 (23.8)
2013–2015 32 (8.9) 10 (8.3) 22 (9.2)

*Matching variable.

WBC: white blood cells, N/L ratio: Neutrophils/Lymphocyte ratio, ESR: erythrocyte sedimentation rate, dsDNA: double-strand deoxyribonucleic acid, Ab: antibody, GCs: glucocorticoids.

aPrednisolone-equivalent.